KPV

Tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH)

What It Is

A very small (3-amino-acid) peptide fragment derived from the C-terminal end of alpha-MSH, studied mainly for anti-inflammatory properties in early-stage research contexts.

Proposed Mechanism

Proposed anti-inflammatory activity potentially independent of the melanocortin-receptor pathway that mediates alpha-MSH's other (e.g., pigmentation) effects — an active and still-developing area of basic research, not an established mechanism.

Areas Researchers Are Investigating

• Gut inflammation research (animal models, e.g., colitis models)
• Skin inflammation research (early-stage, some topical/animal work)
• General anti-inflammatory pathway research

Human Evidence

Minimal to none in the public clinical literature. This is an early-stage research compound, not one with an established human clinical evidence base.

Animal / Preclinical Evidence

The primary evidence base — rodent inflammatory-disease models.

Current FDA / Regulatory Status

Not FDA-approved. Not in a public late-stage human clinical development pathway as of last review.

Known Safety Information

No meaningful human safety data exists publicly.

Limitations of Evidence

Early-stage, animal-model-dominated evidence base; any consumer content should frame this compound clearly as a research-interest area, not a usable intervention.